These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 10947396)

  • 1. Current legal intervention regarding "experimental" treatments must be changed: an analysis of high doses of chemotherapy with autologous bone marrow transplantation for breast cancer patients.
    Smayda E
    J Law Health; 1998-1999; 13(2):257-80. PubMed ID: 10947396
    [No Abstract]   [Full Text] [Related]  

  • 2. Cancer coverage. Why are insurers paying for this "experimental" therapy?
    Med Econ; 1996 Sep; 73(17):38. PubMed ID: 10161873
    [No Abstract]   [Full Text] [Related]  

  • 3. Experimental medical treatments: who should decide coverage?
    Collins JC
    Spec Law Dig Health Care Law; 1998 Jan; (226):9-45. PubMed ID: 10176412
    [No Abstract]   [Full Text] [Related]  

  • 4. High-dose chemotherapy and autologous bone marrow support for breast cancer.
    Peters WP
    Important Adv Oncol; 1991; ():135-50. PubMed ID: 1869274
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical protocol. Purging of autologous stem cell sources with bcl-x(s) adenovirus for women undergoing high-dose chemotherapy for stage IV breast carcinoma.
    Ayash LJ; Clarke M; Adams P; Ferrara J; Ratanatharathorn V; Reynolds C; Roessler B; Silver S; Strawderman M; Uberti J; Wicha M
    Hum Gene Ther; 2001 Nov; 12(16):2023-5. PubMed ID: 11727734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New approach to administrative medical decision-making: evidence-based medicine using high dose chemotherapy/bone marrow transplant for breast cancer.
    Lucey C; Westphal JR
    South Med J; 1998 Feb; 91(2):196-201. PubMed ID: 9496875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Variation in approval by insurance companies of coverage for autologous bone marrow transplantation for breast cancer.
    Peters WP; Rogers MC
    N Engl J Med; 1994 Feb; 330(7):473-7. PubMed ID: 8289855
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Last chance therapies and managed care. Pluralism, fair procedures, and legitimacy.
    Daniels N; Sabin JE
    Hastings Cent Rep; 1998; 28(2):27-41. PubMed ID: 9589291
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ABMT and breast cancer.
    Firshein J
    Healthplan; 1999; 40(4):30-3, 35-7. PubMed ID: 10557735
    [No Abstract]   [Full Text] [Related]  

  • 10. [High dose chemotherapy and autologous bone marrow or stem cell transplantation versus conventional chemotherapy in primary breast cancer. An analysis of a systematic Cochrane review].
    Nielsen DL; Svane IM
    Ugeskr Laeger; 2004 Nov; 166(46):4148-50. PubMed ID: 15565849
    [No Abstract]   [Full Text] [Related]  

  • 11. Variations in insurance coverage for autologous bone marrow transplantation for breast cancer.
    Wingard JR
    N Engl J Med; 1994 Aug; 331(5):330; author reply 330-1. PubMed ID: 8022452
    [No Abstract]   [Full Text] [Related]  

  • 12. Dose intensity studies in breast cancer--autologous bone marrow transplantation.
    Hortobagyi GN; Dunphy F; Buzdar AU; Spitzer G
    Prog Clin Biol Res; 1990; 354B():195-209. PubMed ID: 2236166
    [No Abstract]   [Full Text] [Related]  

  • 13. Autologous bone marrow transplantation for advanced breast cancer.
    Med Lett Drugs Ther; 1991 May; 33(843):39-40. PubMed ID: 2014014
    [No Abstract]   [Full Text] [Related]  

  • 14. Dose intensification using combination alkylating agents and autologous bone marrow support in the treatment of primary and metastatic breast cancer: a review of the Duke Bone Marrow Transplantation Program experience.
    Peters WP
    Prog Clin Biol Res; 1990; 354B():185-94. PubMed ID: 2236164
    [No Abstract]   [Full Text] [Related]  

  • 15. High-dose chemotherapy and autologous hematopoietic stem cell transplantation for metastatic breast cancer: a therapy whose time has passed.
    Vogl DT; Stadtmauer EA
    Bone Marrow Transplant; 2006 Jun; 37(11):985-7. PubMed ID: 16708060
    [No Abstract]   [Full Text] [Related]  

  • 16. Litigating the science of breast cancer treatment.
    Jacobson PD; Rettig RA; Aubry WM
    J Health Polit Policy Law; 2007 Oct; 32(5):785-818. PubMed ID: 17855717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Variations in insurance coverage for autologous bone marrow transplantation for breast cancer.
    Cutler CM; Udvarhelyi IS; Winkenwerder W
    N Engl J Med; 1994 Aug; 331(5):329-30. PubMed ID: 8022449
    [No Abstract]   [Full Text] [Related]  

  • 18. Phase II study of high-dose amsacrine (AMSA) and autologous bone marrow transplantation in patients with refractory metastatic breast cancer.
    Tannir N; Spitzer G; Schell F; Legha S; Zander A; Blumenschein G
    Cancer Treat Rep; 1983 Jun; 67(6):599-600. PubMed ID: 6344995
    [No Abstract]   [Full Text] [Related]  

  • 19. Quality of life among patients with Stage II and III breast carcinoma randomized to receive high-dose chemotherapy with autologous bone marrow support or intermediate-dose chemotherapy: results from Cancer and Leukemia Group B 9066.
    Peppercorn J; Herndon J; Kornblith AB; Peters W; Ahles T; Vredenburgh J; Schwartz G; Shpall E; Hurd DD; Holland J; Winer E
    Cancer; 2005 Oct; 104(8):1580-9. PubMed ID: 16118805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Guillain-Barré syndrome after autologous bone marrow transplantation for breast cancer: report of two cases.
    Myers SE; Williams SF
    Bone Marrow Transplant; 1994 Mar; 13(3):341-4. PubMed ID: 8199578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.